Increased Serum Levels of S100A4 and S100A15 in Individuals Suffering from Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Recently, some S100 proteins have been suggested to play an important role in the pathogenesis of chronic immune-mediated inflammatory diseases and they may constitute valuable biomarkers for these diseases’ diagnosis and monitoring. The objective of the current study was to investigate, for the first time, serum levels of S100A4 and S100A15 in individuals suffering from HS. Furthermore, we assessed the associations between S100A4 and S100A15 serum levels and the severity of disease, CRP serum concentration and some demographic and clinical data. Serum levels of S100A4 and S100A15 were evaluated with the commercially available ELISA kit according to the manufacturer’s instructions. The serum level of S100A4 in individuals with HS was significantly elevated as compared to controls, with the highest level found in the individuals in Hurley stage II. The S100A15 serum level was positively correlated with the CRP concentration and was associated with the severity of the disease. The serum level of S100A15 in the individuals in Hurley stage III was significantly elevated compared to that of the controls and the individuals with HS in Hurley stages I and II. S100A4 and S100A15 may be considered as new serum biomarkers for the monitoring of HS progression, and they may play a role in the pathogenesis of HS by promoting inflammatory process and fibrosis.

Download Full-text

Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis

Journal of Immunology Research ◽

10.1155/2017/5746031 ◽

2017 ◽

Vol 2017 ◽

pp. 1-5 ◽

Cited By ~ 7

Author(s):

Joanna Salomon ◽

Łukasz Matusiak ◽

Danuta Nowicka-Suszko ◽

Jacek C Szepietowski

Keyword(s):

Atopic Dermatitis ◽

Serum Level ◽

Serum Levels ◽

T Helper ◽

C Reactive Protein ◽

Blood Cell Count ◽

Reactive Protein ◽

Helper Response ◽

Severity Of The Disease

Chitinase-3-like protein 1 (YKL-40) is suggested to be associated with type 2 T helper response and atopy. The aim of the study was the evaluation of serum YKL-40 level in atopic dermatitis. The study was performed on 59 patients: 27 males and 32 females, aged from 18 to 64 years. The severity of the disease was assessed by the SCORAD and objective SCORAD indexes. The severity of pruritus was measured by the visual analogue scale. Blood samples were taken to examine serum level of YKL-40, total IgE level, C-reactive protein level, white blood cell count, and neutrophil count. YKL-40 serum levels were significantly higher in patients with atopic dermatitis compared to the controls. There was a positive correlation between YKL-40 concentration and SCORAD, objective SCORAD, and pruritus. This study has shown that YKL-40 serum level is increased in patients with atopic dermatitis and reflects the severity of symptoms.

Download Full-text

Effect of trans-chalcone on hepatic IL-8 through the regulation of miR-451 in male rats

Endocrine Regulations ◽

10.2478/enr-2018-0001 ◽

2018 ◽

Vol 52 (1) ◽

pp. 1-5 ◽

Cited By ~ 3

Author(s):

Elham Karimi-Sales ◽

Sajad Jeddi ◽

Arshad Ghaffari-Nasab ◽

Mina Salimi ◽

Mohammad Reza Alipour

Keyword(s):

Serum Level ◽

Proinflammatory Cytokines ◽

Serum Levels ◽

Male Rats ◽

Positive Effects ◽

Qrt Pcr ◽

Group Control ◽

First Time ◽

Hepatic Level

Abstract Objective. Trans-chalcone is a chalcone with hepatoprotective and anti-inflammatory effects. However, the mechanism of these positive effects, especially on miR-451 as an inflammatory regulator, is poorly understood. In this regard, this microRNA (miRNA) acts by inhibition of hepatic interleukin-8 (IL-8) production in the liver which is one of the main proinflammatory cytokines. Th is study for the first time examined the effect of trans-chalcone on miR-451/IL-8 pathway. Methods. In present study, 21 male rats were randomly divided into 3 groups (n=7 per each group): control which received solvent (NS), groups 2 (N2T) and 3 (N6T), which received transchalcone for 2 and 6 weeks, respectively. Hepatic level of miR-451 was measured by qRT-PCR. Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as well as hepatic level of IL-8 protein were measured. Results. Trans-chalcone decreased hepatic level of IL-8 protein and serum level of ALT aft er 2 weeks of treatment without significant change in hepatic miR-451. Moreover, it increased hepatic level of miR-451 and reduced hepatic IL-8 as well as AST and ALT aft er 6 weeks. Conclusion. Based on the results of present study, miR-451/IL-8 pathway is a possible mechanism for hepatoprotective action of trans-chalcone in long-term.

Download Full-text

P795 Risk of incident paradoxical immune-mediated inflammatory diseases in patients with inflammatory bowel diseases treated with anti-TNF therapies: a nationwide Danish cohort study

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjz203.923 ◽

2020 ◽

Vol 14 (Supplement_1) ◽

pp. S625-S625

Author(s):

D WARD ◽

S Gørtz ◽

N Nyboe Andersen ◽

J Kirchgesner ◽

T Jess

Keyword(s):

Rheumatoid Arthritis ◽

Cohort Study ◽

Inflammatory Bowel Diseases ◽

Hidradenitis Suppurativa ◽

Inflammatory Diseases ◽

Hazard Ratios ◽

Immune Mediated ◽

Bowel Diseases ◽

Lag Period ◽

Inflammatory Bowel

Abstract Background Tumour necrosis factor (TNF) has a central role in the pathophysiology of immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis, psoriasis, hidradenitis suppurativa, and inflammatory bowel diseases (IBD). However, there have been case reports of patients receiving an anti-TNF therapy for one IMID subsequently developing a second IMID. We conducted a nationwide cohort study investigating the risk of incident IMID following anti-TNF exposure in patients with IBD in Denmark. Methods We followed patients with IBD from 1 January 2005 or date of IBD diagnosis (whichever occurred last) to an outcome event including incident diagnosis of hidradenitis suppurativa, arthropathic psoriasis, other forms of psoriasis, or rheumatoid arthritis; or emigration, death or 31 December 2018 (whichever occurred first). Patients were defined as exposed after a 3-month lag period from first anti-TNF infusion throughout follow-up, analogous to an intention-to-treat design. The lag period was censored from analyses to avoid including incipient IMIDs, unlikely to be caused by newly initiated anti-TNF treatment. We excluded patients initiating anti-TNF or with an outcome diagnosis before either 1 January 2005 or IBD diagnosis. We used Cox regression models with age as the underlying timescale, and sex, type of IBD (Crohn’s disease or ulcerative colitis), and calendar period of IBD diagnosis (in 5 year groups) as strata to estimate hazard ratios for each outcome, comparing anti-TNF users and non-users. Results Incidence rates (and 95% confidence intervals [CI]) as events per 100 000 person-years among anti-TNF users and non-users were, respectively, 138 (109–173) and 25.6 (22.0–29.7) for hidradenitis suppurativa, 26.3 (15.6–44.4) and 7.81 (5.95–10.2) for arthropathic psoriasis, 1177 (1085–1277) and 204 (121–189) for other forms of psoriasis, and 152 (121–189) and 95.6 (88.5–103) for rheumatoid arthritis. Hazard ratios (and 95% C.I.) were increased for hidradenitis suppurativa 2.91 (2.15–3.94), arthropathic psoriasis 2.62 (1.40–4.93), other forms of psoriasis 4.76 (4.27–5.31), and rheumatoid arthritis 2.35 (1.83–3.01). Conclusion The results indicate that patients with IBD receiving anti-TNF have an increased risk of IMIDs. An almost 5-fold increase in the risk of psoriasis is consistent with previous reports of psoriasiform skin lesions related to anti-TNF use. However, as more severe IBD is likely to be associated with both initiating anti-TNF and the incidence of other inflammatory diseases, the results are subject to confounding by indication. Thus, these results should be considered preliminary, and we plan to further address confounding by using propensity score methods.

Download Full-text

Tan spot development peculiarities in Latvia

Plant Protection Science ◽

10.17221/10497-pps ◽

2017 ◽

Vol 38 (SI 2 - 6th Conf EFPP 2002) ◽

pp. 381-383

Author(s):

B. Bankina

Keyword(s):

Field Experiments ◽

Tan Spot ◽

Severity Of Disease ◽

Pyrenophora Tritici Repentis ◽

Wheat Diseases ◽

Flowering Rate ◽

Severity Of The Disease ◽

First Time ◽

And Training ◽

Very High

Tan spot, caused by Pyrenophora tritici-repentis (Died.) Drechs., anamorph Drechslera tritici-repentis is one of the most important wheat diseases in the world, especially in the regions of intensive wheat growing. Tan spot had established for the first time in Latvia in 1994. Epidemic of this disease was observed in Latvia in 1998. Development of tan spot were investigated in field experiments at the Research and Training Farm “Peterlauki” of Latvia University of Agriculture in 1998–2001. Level of incidence and severity of tan spot differed depending on varieties and years. Severity of the disease was 16–71% in 1999; 0.1–5% in 2000 and 4–18% in 2001 depending on varieties at the time of ripening. 1999 summer was extremely dry, and development of disease was not observed. Explosion of disease was observed at the second half of June in 2000 and 2001, without reference to varieties. Date of increasing start differed, but in all cases important development was observed after flowering. Rate of increasing of disease was very high, during two weeks severity of disease increased from 0.1 till maximum of severity. Amount and frequency of rainy differed in 2000 and 2001, but increase on disease was very similar, it means, we need more information about favourable conditions for Drechslera tritici-repentis. Sexual stage Pyrenophora tritici-repentis was observed in Latvia for the first time. Further investigations are necessary, because relationships between meteorological conditions and stages of development are unclear.

Download Full-text

Serum level of stem cell factor and its soluble receptor in aspirin-exacerbated respiratory disease

Immunotherapy ◽

10.2217/imt-2019-0042 ◽

2019 ◽

Vol 11 (15) ◽

pp. 1283-1291 ◽

Cited By ~ 2

Author(s):

Rasoul Nasiri Kalmarzi ◽

Aida Foroutan ◽

Mohammad Abdi ◽

Pedram Ataee ◽

Ali Jalili ◽

...

Keyword(s):

Stem Cell ◽

Serum Level ◽

Stem Cell Factor ◽

Growth Factor Receptor ◽

Serum Levels ◽

Case Group ◽

Soluble Receptor ◽

Serum Samples ◽

Inflammatory Processes ◽

Severity Of The Disease

Aim: Stem cell factor (SCF) may be associated with inflammatory processes leading to aspirin-induced asthma. This study evaluated the relationship between serum level of SCF and its soluble receptor with aspirin-induced asthma. Methods & materials: Twenty-five patients and 25 healthy controls were enrolled in this study. The concentration of SCF and mast/stem cell growth factor receptor (C-kit) was determined in serum samples. Spirometry and rhinometry were performed to determine the severity of the disease. p < 0.05 were considered significant. Results: The serum levels of SCF and C-kit receptor were significantly higher in the case group. The serum SCF and C-kit level had a significant positive correlation with the severity of asthma, disease duration and nasal obstruction. Conclusion: Our findings suggest that SCF and C-kit receptors have a direct effect on the severity of aspirin-induced asthma.

Download Full-text

THE THYROTROPHIN RESPONSE TO THYROTROPHIN RELEASING HORMONE DURING TREATMENT IN PATIENTS WITH GRAVES' DISEASE

Acta Endocrinologica ◽

10.1530/acta.0.0850335 ◽

1977 ◽

Vol 85 (2) ◽

pp. 335-344 ◽

Cited By ~ 9

Author(s):

E. Haug ◽

H. M. M. Frey ◽

T. Sand

Keyword(s):

Serum Level ◽

Thyroid Hormones ◽

Pituitary Gland ◽

Serum Levels ◽

Graves Disease ◽

Trh Test ◽

Thyrotrophin Releasing Hormone ◽

Releasing Hormone ◽

First Time ◽

Serum Tsh

ABSTRACT Thyrotrophin releasing hormone (TRH) tests were performed at 4 or 8 weeks intervals, after the initiation of anti-thyroid treatment in 15 patients with Graves' disease. All TRH tests were negative as long as the serum levels of thyroxine (T4) and triiodothyronine (T3) were elevated, and normalization of the serum levels of these hormones always occurred before the response to iv TRH was restored. In 13 patients the time from the patients for the first time were registered as biochemically euthyroid varied from 0–9 months (mean 3.1 months), before normal TRH response was restored. Two patients were still TRH non-responsive at the end of the study, even though they had been biochemically euthyroid for as long as 17 and 18.5 months. The TRH test, therefore, is not helpful in the evaluation of the effect of anti-thyroid treatment in patients with Graves' disease. There was an increase in the serum level of thyrotrophin (TSH) from 3.4 ± 0.3 (sem) to 4.3 ± 0.5 (sem) ng/ml (P <0.05), and a decrease in the serum level of total T4 from 19.4 ± 1.1 (sem) to 5.8 ± 0.8 (sem) μg/100 ml in 13 patients from the first examination until the last time they were examined before restored TRH response. This finding shows that the pituitary gland has retained its ability to synthesize and secrete TSH even though no TSH could be released by iv TRH. In 6 TRH non-responsive patients with Graves' disease, serum TSH levels were suppressed from 2.5 ±1.2 (sem) ng/ml before the administration of a single dose of 3 mg T4 orallly, to 0.9 ± 0.2 (sem) ng/ml, 7 days after the T4 administration. Thus, the negative feed-back effect on the pituitary gland of the thyroid hormones is operating in these patients. This finding indicates that the TRH non-responsiveness in euthyroid patients with Graves' disease is not due to pituitary depletion of TSH, since the negative feed-back effect of the thyroid hormones is operating normally.

Download Full-text

25-hydroxyvitamin D3 Concentration in Serum and Cerebrospinal Fluid of Patients with Remitting-relapse Multiple Sclerosis

Prague Medical Report ◽

10.14712/23362936.2014.18 ◽

2013 ◽

Vol 114 (3) ◽

pp. 162-171 ◽

Cited By ~ 6

Author(s):

Ali Moghtaderi ◽

G. H. Tamadon ◽

F. Haghighi

Keyword(s):

Multiple Sclerosis ◽

Cerebrospinal Fluid ◽

Statistical Difference ◽

Inflammatory Diseases ◽

Diagnostic Procedures ◽

Serum Levels ◽

Study Groups ◽

Control Group ◽

And Control ◽

First Time

There is epidemiological, geographical and immunological evidence suggesting that low environmental supplies of vitamin D3 may act as a  risk factor for developing multiple sclerosis (MS), possibly due to dysfunction in  the immunomodulatory properties of 25-hydroxyvitamin D3 (25-OH-D3) in  the brain. The objective of this study is to measure the serum and cerebrospinal fluid (CSF) concentrations of 25-OH-D3 in  MS patients during their relapsing phase. 52 patients with remitting-relapse and 58 patients with other non-inflammatory diseases of central and peripheral nervous system were entered into the study. Patients in  both groups were admitted for the first time to do diagnostic procedures and they were not on any other treatment for neurological disorders. The means and medians for serum levels of 25-OH-D3 in  MS patients and control group were 10.64 ± 9.2 ng/ml (median: 9.6 ng/ml) and 13.23 ± 17.56 ng/ml (median: 11.90 ng/ml), respectively (p=0.328). CSF concentrations for the same values were 2.02 ± 1.94 ng/ml (median: 0.23 ng/ml) and 3.28 ± 2.96 (median: 0.29 ng/ml), respectively (p=0.242). The differences between calculated numbers of serum/CSF ratios were not statistically significant too. The serum and CSF concentrations of 25-OH-D3 in  MS group were lower than the control counterpart without any statistical difference and the authors did not find any influence of serum 25-OH-D3 concentration on the CSF concentration based on the non-significant statistical difference between the serum/CSF ratios in  two study groups of MS patients and control cases.

Download Full-text

Genetic Variation in TNF-α, its Relation with Inflammatory Biomarkers and Susceptibility to Rheumatoid Arthritis

Annals of Immunology & Immunotherapy ◽

10.23880/aii-16000122 ◽

2020 ◽

Vol 2 (2) ◽

Author(s):

Khadiga Ahmed Ismail

Keyword(s):

Rheumatoid Arthritis ◽

Serum Level ◽

Functional Disability ◽

Serum Levels ◽

Amplification Refractory Mutation System ◽

Reactive Protein ◽

Tnf Α ◽

Mutation System ◽

Potential Factor ◽

Factor Α

Background: Tumor necrosis Factor-α (TNF-α) is encoded and controlled by TNF-α gene, which is involved in rheumatoid arthritis (RA) susceptibility. This research aimed to identify genetic variations of TNF-α (G308A) and to establish its association with inflammatory markers in Rheumatoid Arthritis predisposition. Methods: In the present study, fifty RA patients and fifty volunteers were involved and evaluated for the C-reactive protein, rheumatoid factor, and TNF-α were estimated by ELISA, Erythrocyte Sedimentation Rate (ESR) by Wintergreen method and for TNF-α-308 G>A polymorphism by polymerase chain reaction with amplification refractory mutation system (PCR-ARMS). Results: The CRP, RF, ESR and TNF-α were significantly elevated in RA patients relative to controls. The serum level TNF-α was also significantly elevated in female patients and in patients ≥50 years. Analysis of TNF-308 gene polymorphism revealed that GG genotypes were more prevalent in RA patients than in the healthy individuals and that GG genotype may be a potential factor to RA. The G allele was more common in RA than in the control. Elevated TNF-α serum levels were significantly associated the GG genotype and functional disability in RA patients. Conclusion: TNF-α promoter 308polymorphism GG genotype may be considered as a risk factor for RA and the TNF-α serum level was significantly related to the functional disability in the disease.

Download Full-text

Cardiovascular Risk Assessement in Osteoporotic Patients Using Osteoprotegerin as a Reliable Predictive Biochemical Marker

Ibn AL- Haitham Journal For Pure and Applied Science ◽

10.30526/2017.ihsciconf.1798 ◽

2018 ◽

pp. 253

Author(s):

Noora Wael Rasheed ◽

Ooroba Jameel Taresh

Keyword(s):

Cardiovascular Disease ◽

Metabolic Syndrome ◽

Cardiovascular Risk ◽

Serum Level ◽

Biochemical Markers ◽

Hdl Cholesterol ◽

Predictive Marker ◽

Serum Levels ◽

Arterial Calcification ◽

The Metabolic Syndrome

Some studies indicated a relationship between increased serum levels of osteoprotegerin with arterial calcification and as a result, it leads to the risk of cardiovascular disease. In our study group we selected patients with osteoporosis, with similar age and body mass index for the assessment of the relationship between cardiovascular disease and osteoprotegerin serum level. We took into account the analysis of correlation and association between the presence of distinct patterns of atherosclerosis and associated diseases like high blood pressure, diabetes mellitus, low HDL cholesterol, increased LDL cholesterol, increased triglycerides and was the case of presence of any type of dyslipidemia, in case of pre-existent treatment. Objective of study was the assessment of osteoprotegerin value as predictive marker for cardiovascular and metabolic risk in osteoporotic patients. Our results showed significant correlations of parathyroid hormone, osteocalcin and biochemical markers of bone with glucose metabolism and lipid were found in our research, maintaining crosstalk between calcium and biochemical markers of bone and cardiovascular risk. The serum level of Osteoprotegerin has been shown to have a large predictive value for the metabolic syndrome as a cardiovascular risk standard in patients with osteoporosis. The osteoprotegerin serum levels were increased in the patients with metabolic syndrome as a protective response facing the atherosclerotic lesions.

Download Full-text